[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.82.105. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Citations 0
Correction
July 7, 1999

Author Omitted

JAMA. 1999;282(1):29. doi:10.1001/jama.282.1.29

In the Editorial entitled "Understanding Parkinson Disease" published in the January 27, 1999, issue of THE JOURNAL (1999;281:376-378), selegiline was identified as an MAO type A inhibitor rather than a type B inhibitor. On page 377, the sentence should have read, "Selegiline is a monoamine oxidase type B inhibitor that limits the formation of free radicals derived from oxidation of dopamine, and application of this agent in clinical trials suggests an effect on disease progression consistent with a neuroprotective action.23-25"

×